Compare UVSP & SPRY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | UVSP | SPRY |
|---|---|---|
| Founded | 1876 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 983.8M | 823.2M |
| IPO Year | 1994 | 2020 |
| Metric | UVSP | SPRY |
|---|---|---|
| Price | $38.03 | $8.16 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | $36.67 | ★ $40.00 |
| AVG Volume (30 Days) | 178.6K | ★ 1.5M |
| Earning Date | 04-22-2026 | 05-11-2026 |
| Dividend Yield | ★ 2.44% | N/A |
| EPS Growth | ★ 21.32 | N/A |
| EPS | ★ 0.96 | N/A |
| Revenue | ★ $328,056,000.00 | $84,278,000.00 |
| Revenue This Year | $11.65 | $87.40 |
| Revenue Next Year | $4.77 | $81.64 |
| P/E Ratio | $39.14 | ★ N/A |
| Revenue Growth | ★ 9.64 | N/A |
| 52 Week Low | $27.91 | $6.66 |
| 52 Week High | $38.71 | $18.63 |
| Indicator | UVSP | SPRY |
|---|---|---|
| Relative Strength Index (RSI) | 64.83 | 48.76 |
| Support Level | $32.00 | $7.90 |
| Resistance Level | $38.22 | $8.61 |
| Average True Range (ATR) | 1.02 | 0.40 |
| MACD | 0.01 | 0.02 |
| Stochastic Oscillator | 80.12 | 54.40 |
Univest Financial Corp is engaged in domestic banking services for individuals, businesses, municipalities and non-profit organizations. The bank has three operating segments; Banking segment provides financial services including a full range of banking services such as deposit taking, loan origination, and servicing, mortgage banking, other general banking services, and equipment lease financing, Wealth Management segment offers investment advisory, financial planning, trust and brokerage services, and The Insurance segment includes a full-service insurance brokerage agency offering commercial property and casualty insurance, employee benefits solutions, personal insurance lines and human resources consulting. It generates majority of its revenue from the banking segment.
ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the commercialization and development of neffy (currently identified in the European Union (EU) and United Kingdom (U.K.) by the trade name EURneffy and in China) for needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. Neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows Neffy to safely provide intranasal delivery of epinephrine at a low dose within the exposures of approved injectable products across a range of dosing conditions.